PIK3CA and lipoma: Alpelisib has been reported to effectively inhibit growth in lipoma cells deficient in PTEN derived from PTEN hamartoma tumor syndrome patients, but loss of function PTEN mutations has also been reported as a mechanism of resistance to alpelisib and fulvestrant in PIK3CA mutant hormone receptor-positive breast cancer [27, 28].